共 279 条
[1]
Ommen SR(2020)2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation 142 e533-e557
[2]
Mital S(2020)Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism Eur J Prev Cardiol 27 1906-1908
[3]
Burke MA(2022)Management of Hypertrophic Cardiomyopathy JACC State-of-the-Art Review J Am Coll Cardiol 79 390-414
[4]
Day SM(2013)Hypertrophic cardiomyopathy Lancet 381 242-255
[5]
Deswal A(2017)Perspectives on the Overall Risks of Living With Hypertrophic Cardiomyopathy Circulation 135 2317-2319
[6]
Elliott P(2018)Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy Circulation 138 1387-1398
[7]
Evanovich LL(2020)Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy J Thromb Thrombolysis 49 177-183
[8]
Hung J(2020)Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies Int J Mol Sci 21 6462-5073
[9]
Joglar JA(2017)Prognostic Significance of Plasma High-Sensitivity C-Reactive Protein in Patients With Hypertrophic Cardiomyopathy J Am Heart Assoc 6 e004529-13
[10]
Kantor P(2017)Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy Am J Transl Res 9 5063-39.e14